Tepoditamab (MCLA-117) is a bispecific monoclonal antibody targeting CLEC12A on myeloid cells and CD3 on cytotoxic T cells. As a myeloid differentiation antigen, CLEC12A allows the compound to eliminate AML leukemia progenitor and stem cells through T cell-mediated proliferative lysis, making it valuable in acute myeloid leukemia (AML) research [1].
CAS Nummer:
[2044679-53-8]
Target-Kategorie:
Integrin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
